Targeted radionuclide therapy against GARP expressing T regulatory cells after tumour priming with external beam radiotherapy in a murine syngeneic model.

Fiche publication

Date publication

octobre 2024

Journal

Heliyon

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen , Dr MIRJOLET Céline , Dr COLLIN Bertrand , Dr BELLAYE Pierre-Simon , Pr KOHLI Evelyne

Tous les auteurs :
Bellaye PS, Dias AM, Vrigneaud JM, Bouchard A, Moreau M, Petitot C, Bernhard C, Claron M, Froidurot L, Morgand V, Guillemin M, Monterrat M, Mirjolet C, Garrido C, Kohli E, Collin B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39498075

Résumé

Radiation therapy (RT) exerts its anti-tumour efficacy by inducing direct damage to cancer cells but also through modification of the tumour microenvironment (TME) by inducing immunogenic antitumor response. Conversely, RT also promotes an immunosuppressive TME notably through the recruitment of regulatory T cells (Tregs). Glycoprotein A repetitions predominant (GARP), a transmembrane protein highly expressed by activated Tregs, plays a key role in the activation of TGF-β and thus promotes the immunosuppressive action of Tregs. The development of a theranostic approach targeting GARP combining imaging and targeted radionuclide therapy (TRT) was carried out.